Psyence Group (TSE:PSYG) has released an update.
Psyence Group, a life science biotech company, has announced a strategic debt-for-equity swap with its associate, Psyence Biomedical, converting a debt obligation into over two million shares. This financial maneuver aims to enhance portfolio flexibility and liquidity, while also providing a clearer market valuation for Psyence Group’s investment.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.
